FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 206 filers reported holding FATE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $213,433 | -55.4% | 100,676 | +0.1% | 0.00% | – |
Q2 2023 | $478,547 | -14.6% | 100,535 | +2.3% | 0.00% | – |
Q1 2023 | $560,270 | -43.8% | 98,293 | -1.1% | 0.00% | -100.0% |
Q4 2022 | $996,885 | -54.9% | 99,386 | +0.5% | 0.00% | -50.0% |
Q3 2022 | $2,211,722 | -3.6% | 98,899 | +7.1% | 0.00% | 0.0% |
Q2 2022 | $2,293,368 | -36.9% | 92,314 | +0.2% | 0.00% | 0.0% |
Q1 2022 | $3,635,744 | +48.8% | 92,139 | +123.9% | 0.00% | +100.0% |
Q4 2021 | $2,444,000 | -0.6% | 41,145 | -0.8% | 0.00% | -50.0% |
Q3 2021 | $2,459,000 | -37.0% | 41,496 | -7.7% | 0.00% | -33.3% |
Q2 2021 | $3,904,000 | +10.9% | 44,979 | +5.3% | 0.00% | 0.0% |
Q1 2021 | $3,521,000 | -9.6% | 42,700 | -0.3% | 0.00% | -25.0% |
Q4 2020 | $3,895,000 | +138.1% | 42,830 | +4.7% | 0.00% | +100.0% |
Q3 2020 | $1,636,000 | +33.8% | 40,923 | +9.1% | 0.00% | +100.0% |
Q2 2020 | $1,223,000 | +41.6% | 37,519 | -3.6% | 0.00% | 0.0% |
Q1 2020 | $864,000 | +37.8% | 38,908 | +21.5% | 0.00% | 0.0% |
Q4 2019 | $627,000 | +22.5% | 32,016 | -3.3% | 0.00% | 0.0% |
Q3 2019 | $512,000 | -23.9% | 33,117 | -0.0% | 0.00% | 0.0% |
Q2 2019 | $673,000 | -4.0% | 33,129 | -17.0% | 0.00% | 0.0% |
Q1 2019 | $701,000 | +56.1% | 39,929 | +14.2% | 0.00% | 0.0% |
Q4 2018 | $449,000 | -19.0% | 34,962 | +2.8% | 0.00% | 0.0% |
Q3 2018 | $554,000 | +28.2% | 34,019 | -10.8% | 0.00% | – |
Q2 2018 | $432,000 | +20.0% | 38,120 | +3.1% | 0.00% | – |
Q1 2018 | $360,000 | +77.3% | 36,977 | +10.9% | 0.00% | – |
Q4 2017 | $203,000 | +147.6% | 33,337 | +61.4% | 0.00% | – |
Q3 2017 | $82,000 | +8100.0% | 20,651 | +9244.3% | 0.00% | – |
Q2 2017 | $1,000 | 0.0% | 221 | +20.1% | 0.00% | – |
Q1 2017 | $1,000 | – | 184 | 0.0% | 0.00% | – |
Q4 2016 | $0 | -100.0% | 184 | 0.0% | 0.00% | – |
Q3 2016 | $1,000 | – | 184 | 0.0% | 0.00% | – |
Q2 2016 | $0 | – | 184 | 0.0% | 0.00% | – |
Q1 2016 | $0 | -100.0% | 184 | 0.0% | 0.00% | – |
Q4 2015 | $1,000 | 0.0% | 184 | 0.0% | 0.00% | – |
Q3 2015 | $1,000 | 0.0% | 184 | 0.0% | 0.00% | – |
Q2 2015 | $1,000 | – | 184 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |